- Home
- ONON vs BIIB Comparison
ONON vs BIIB Comparison
Compare ONON & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONON
- BIIB
- Stock Information
- Founded
- ONON 2010
- BIIB 1978
- Country
- ONON Switzerland
- BIIB United States
- Employees
- ONON N/A
- BIIB N/A
- Industry
- ONON Shoe Manufacturing
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ONON Consumer Discretionary
- BIIB Health Care
- Exchange
- ONON Nasdaq
- BIIB Nasdaq
- Market Cap
- ONON 11.4B
- BIIB 18.7B
- IPO Year
- ONON 2021
- BIIB 1991
- Fundamental
- Price
- ONON $42.44
- BIIB $164.84
- Analyst Decision
- ONON Strong Buy
- BIIB Buy
- Analyst Count
- ONON 20
- BIIB 24
- Target Price
- ONON $62.50
- BIIB $174.62
- AVG Volume (30 Days)
- ONON 9.5M
- BIIB 1.7M
- Earning Date
- ONON 11-12-2025
- BIIB 10-30-2025
- Dividend Yield
- ONON N/A
- BIIB N/A
- EPS Growth
- ONON 74.51
- BIIB N/A
- EPS
- ONON 0.84
- BIIB 10.97
- Revenue
- ONON $3,607,815,596.00
- BIIB $10,065,900,000.00
- Revenue This Year
- ONON $30.53
- BIIB $2.97
- Revenue Next Year
- ONON $23.83
- BIIB N/A
- P/E Ratio
- ONON $50.21
- BIIB $15.01
- Revenue Growth
- ONON 33.26
- BIIB 4.77
- 52 Week Low
- ONON $34.38
- BIIB $110.04
- 52 Week High
- ONON $64.05
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- ONON 59.84
- BIIB 71.92
- Support Level
- ONON $34.38
- BIIB $151.83
- Resistance Level
- ONON $44.87
- BIIB $157.79
- Average True Range (ATR)
- ONON 1.77
- BIIB 5.37
- MACD
- ONON 0.47
- BIIB 1.11
- Stochastic Oscillator
- ONON 76.22
- BIIB 88.75
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.